Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

Aceves, Seema S.; Collins, Margaret H.; Rothenberg, Marc E.; Furuta, Glenn T.; Gonsalves, Nirmala

doi:10.1016/j.jaci.2019.11.012

Cited by 19 publications

(6 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medical organisations should work with patient support organisations such as the Eos Network in developing patient educational material (EosNetwork.org). Also the combination of medical and patient input into the direction of research, such as that of Consortium of Eosinophilic Gastrointestinal disease Researchers (CEGIR), 243 is a clear example of good practice in research. Due to the availability of global internet connectivity, there is value in ensuring that these organisations have a global perspective.…”

Section: Future Researchmentioning

confidence: 99%

British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults

Dhar

Haboubi

Attwood

et al. 2022

Gut

121

View full text Add to dashboard Cite

BackgroundEosinophilic oesophagitis (EoE) is an increasingly common cause of dysphagia in both children and adults, as well as one of the most prevalent oesophageal diseases with a significant impact on physical health and quality of life. We have provided a single comprehensive guideline for both paediatric and adult gastroenterologists on current best practice for the evaluation and management of EoE.MethodsThe Oesophageal Section of the British Society of Gastroenterology was commissioned by the Clinical Standards Service Committee to develop these guidelines. The Guideline Development Group included adult and paediatric gastroenterologists, surgeons, dietitians, allergists, pathologists and patient representatives. The Population, Intervention, Comparator and Outcomes process was used to generate questions for a systematic review of the evidence. Published evidence was reviewed and updated to June 2021. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system was used to assess the evidence and make recommendations. Two rounds of voting were held to assess the level of agreement and the strength of recommendations, with 80% consensus required for acceptance.ResultsFifty-seven statements on EoE presentation, diagnosis, investigation, management and complications were produced with further statements created on areas for future research.ConclusionsThese comprehensive adult and paediatric guidelines of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition are based on evidence and expert consensus from a multidisciplinary group of healthcare professionals, including patient advocates and patient support groups, to help clinicians with the management patients with EoE and its complications.

show abstract

Section: Future Researchmentioning

confidence: 99%

British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults

Dhar

Haboubi

Attwood

et al. 2022

Gut

121

View full text Add to dashboard Cite

show abstract

“…3,4 A recently reported histology scoring system for EoE evaluates features in addition to eosinophilic inflammation that correlate with symptoms, and can be used to determine remission; however, peak eosinophil count remains the gold standard for diagnosis. [5][6][7] By contrast, eosinophilic gastritis and duodenitis (EOG/EoD) present with a constellation of generally nonspecific symptoms (early satiety, nausea and vomiting, abdominal pain and cramping, bloating, and diarrhea) that overlap with other common GI conditions, such as functional dyspepsia or irritable bowel syndrome. This broad-based clinical presentation, together with low disease awareness, perceived rarity, and the frequent absence of significant endoscopic findings 8 make EGIDs an uncommon clinical suspicion.…”

mentioning

confidence: 99%

Quantification of Mucosal Eosinophils for the Histopathologic Diagnosis of Eosinophilic Gastritis and Duodenitis

Turner

Collins

Walker

et al. 2021

American Journal of Surgical Pathology

Self Cite

View full text Add to dashboard Cite

Eosinophilic gastrointestinal diseases, specifically eosinophilic gastritis and duodenitis, are chronic inflammatory conditions characterized by persistent gastrointestinal (GI) symptoms and elevated levels of activated eosinophils in the GI tract. Both clinical and endoscopic findings are nonspecific, no clinical or histopathologic diagnostic guidelines are published, and disease awareness is low, both among clinicians and amongst pathologists, who tend to overlook mild or moderate increases in the density of eosinophils in GI biopsy specimens. Yet, evaluating and, at times, counting eosinophils in GI biopsies may have important clinical implications: the numbers of tissue eosinophils correlate with clinical manifestations, can be used as determinants of effective management, and are used to assess the effects of treatment. A most persuasive argument for providing a count rather than a value judgment is that patients read reports, understand numbers, and use them to help to understand the course of their disease. The objective of this primer is to provide pathologists with the tools to incorporate a quantitative assessment of eosinophilia in the diagnosis of gastric and duodenal biopsy specimens and to develop a systematic approach to their evaluation, counting, and reporting. To achieve this aim, we present our general approach to the biopsy (where to count), followed by details on the characteristics of a countable eosinophil (what to count), and provide with a set of suggestions on the counting methods (how to count). We conclude with suggestions on how to report GI tissue eosinophilia in a manner that alerts clinicians and prompts pertinent management steps.

show abstract

“…In addition to the optimised delivery of educational resources described above, patient advocacy groups will continue to be a critical resource for patients and their support network [ 37 , 39 , 40 ]. Coupled with these improvements in HCP and patient education, we recognise that there is also a need for wider public awareness about the prevalence and burden of EADs, especially with respect to their impacts on patient HRQoL.…”

Section: Charter Purposementioning

confidence: 99%

Improving Care in Eosinophil-Associated Diseases: A Charter

Jackson

Akuthota

Andradas³

et al. 2022

Adv Ther

View full text Add to dashboard Cite

Eosinophil-associated diseases (EADs) are a range of heterogeneous conditions in which eosinophils are believed to play a critical pathological role. EADs include common illnesses such as eosinophilic asthma and chronic rhinosinusitis and rare conditions such as hypereosinophilic syndromes (HES) and eosinophilic gastrointestinal disorders (EGIDs). EADs are associated with substantial burdens for the patient, including chronic, debilitating symptoms, increased financial burden, decreased health-related quality of life, and the need for repeated visits to multiple different healthcare professionals (HCPs), emergency departments, and/or hospitals. Poor EAD recognition by HCPs often contributes to delayed diagnoses, which further delays patient access to appropriate care and effective treatments, contributing to poor health outcomes. The objective of this charter is to outline key patient rights and expectations with respect to the management of their condition(s) and to set forth an ambitious action plan to improve health outcomes for patients with EADs: (1) people with EADs, their caretakers, HCPs, and the public must have greater awareness and education about EADs; (2) people with EADs must receive a timely, accurate diagnosis; (3) all people with EADs must have access to an appropriate multidisciplinary team, when necessary; and (4) people with EADs must have access to safe and effective treatment options without unnecessary regulatory delays. The principles described in this charter demonstrate the core elements of quality care that people with EADs must receive, and they represent clear steps by which to reduce patient and caregiver burden and improve patient outcomes. We urge HCPs, healthcare systems, and policymakers worldwide to swiftly adopt these principles to ensure patients with EADs have an accurate diagnosis in a timely manner and access to high-level care and treatment in an appropriate setting.

show abstract

Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

Cited by 19 publications

References 72 publications

British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults

British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults

Quantification of Mucosal Eosinophils for the Histopathologic Diagnosis of Eosinophilic Gastritis and Duodenitis

Improving Care in Eosinophil-Associated Diseases: A Charter

Contact Info

Product

Resources

About